Press Releases

Press Releases

Summary Toggle PDL BioPharma to Complete Spin-Off of LENSAR, Inc. on October 1, 2020

Declares Record Date of September 22, 2020 and Expected Share Distribution Date of October 1, 2020 Conference call with slide presentation today beginning at 4:30 p.m. Eastern time INCLINE VILLAGE, Nev. , Sept. 10, 2020 /PRNewswire/ -- PDL BioPharma, Inc.

Sep 10, 2020
Summary Toggle PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital

INCLINE VILLAGE, Nev. , Sept. 9, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA (collectively " Noden ") to Stanley Capital .

Sep 9, 2020
Summary Toggle PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation

INCLINE VILLAGE, Nev. , Aug. 31, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella ® , Zalviso ® , and Coflex ® (collectively the "Royalties") to SWK

Aug 31, 2020
Summary Toggle PDL BioPharma Announces Offer to Purchase Convertible Notes Due 2021 and 2024

INCLINE VILLAGE, Nev. , Aug. 28, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that holders of its 2.75% Convertible Senior Notes due in December 2021 (the "2021 Notes") and in December 2024 (the "2024 Notes" and together with the 2021 Notes, the

Aug 28, 2020
Summary Toggle PDL BioPharma Announces Filing of a Form 10 Registration Statement with the Securities and Exchange Commission for a Potential Spin-off of LENSAR to PDL's Stockholders

INCLINE VILLAGE, Nev. , Aug. 26, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that its majority owned medical device subsidiary, LENSAR, Inc. (" LENSAR "), has filed a registration statement on Form 10 with the Securities and Exchange Commission

Aug 26, 2020
Summary Toggle PDL BioPharma Enters Into Settlement Agreement with Wellstat

INCLINE VILLAGE, Nev. , Aug. 12, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a settlement agreement (the "Settlement Agreement") with related entities of Defined Diagnostics, LLC (f/k/a Wellstat Diagnostics, LLC ) (" Wellstat

Aug 12, 2020
Summary Toggle PDL BioPharma Reports 2020 Second Quarter Financial Results

- Accomplished Important Asset Monetization Milestones with the Distribution of Evofem Biosciences Shares to PDL Stockholders and the Anticipated Sale of Noden to Stanley Capital - Announced the Filing of a Form 10 with SEC for Potential Spin-off of LENSAR - Continues to Seek Potential

Aug 6, 2020
Summary Toggle PDL BioPharma to Announce Second Quarter 2020 Financial Results on August 6, 2020

INCLINE VILLAGE, Nev. , July 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its second quarter 2020 financial results for the period ended June 30, 2020 , on Thursday, August 6, 2020 , after market close.

Jul 30, 2020
Summary Toggle PDL BioPharma Enters Into Agreement for the Divestiture of the Noden Pharmaceutical Business to Stanley Capital

INCLINE VILLAGE, Nev. , July 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing of a definitive agreement for the sale of 100% of the outstanding stock in its wholly owned subsidiaries Noden Pharma DAC and Noden USA (collectively " Noden ")

Jul 30, 2020
Summary Toggle PDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL Stockholders

INCLINE VILLAGE, Nev. , May 21, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that it has completed its previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc.

May 21, 2020
Summary Toggle PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders

INCLINE VILLAGE, Nev. , May 18, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the final distribution ratio for the previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc.

May 18, 2020
Summary Toggle PDL BioPharma Reports 2020 First Quarter Financial Results

Provides Update to Asset Monetization Plan Discusses Impact of COVID-19 on Operations and Monetization Plan - Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today - INCLINE VILLAGE, Nev. , May 7, 2020 /PRNewswire/ -- PDL BioPharma, Inc.

May 7, 2020
Summary Toggle PDL BioPharma Declares Dividend of Evofem Biosciences Common Stock to PDL Stockholders

INCLINE VILLAGE, Nev. , May 5, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that the Company's Board of Directors has approved a distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc.

May 5, 2020
Summary Toggle PDL BioPharma to Announce First Quarter 2020 Financial Results on May 7, 2020

INCLINE VILLAGE, Nev. , April 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its first quarter 2020 financial results for the period ended March 31, 2020 , on Thursday, May 7, 2020 , after market close.

Apr 30, 2020
Summary Toggle PDL BioPharma Reports 2019 Fourth Quarter and Full Year Financial Results and Announces Plan to Dissolve the Company by Year-End 2020

- 2019 Revenue Guidance Exceeded - - Monetization Process Underway - - PDL Board Approved Plan of Complete Liquidation and Plans to Seek Stockholder Approval for Dissolution of the Company - - Targeting to File a Certificate of Dissolution under Delaware Law by Year-End 2020 - - Conference Call at

Mar 11, 2020